|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/26/21 Acadia Healthcare Co., Inc. 10-K 12/31/20 139:21M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.02M
2: EX-2.1 Plan of Acquisition, Reorganization, Arrangement, HTML 75K
Liquidation or Succession
3: EX-2.2 Plan of Acquisition, Reorganization, Arrangement, HTML 348K
Liquidation or Succession
4: EX-4.13 Instrument Defining the Rights of Security Holders HTML 57K
5: EX-21 Subsidiaries List HTML 100K
6: EX-22 Published Report re: Matters Submitted to a Vote HTML 45K
of Security Holders
7: EX-23 Consent of Expert or Counsel HTML 36K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 43K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 43K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 39K
11: EX-32.2 Certification -- §906 - SOA'02 HTML 38K
18: R1 Document and Entity Information HTML 102K
19: R2 Consolidated Balance Sheets HTML 146K
20: R3 Consolidated Balance Sheets (Parenthetical) HTML 51K
21: R4 Consolidated Statements of Operations HTML 151K
22: R5 Consolidated Statements of Operations HTML 38K
(Parenthetical)
23: R6 Consolidated Statements of Comprehensive Income HTML 71K
(Loss)
24: R7 Consolidated Statements of Comprehensive Income HTML 41K
(Loss) (Parenthetical)
25: R8 Consolidated Statements of Equity HTML 76K
26: R9 Consolidated Statements of Cash Flows HTML 178K
27: R10 Description of Business and Basis of Presentation HTML 43K
28: R11 Summary of Significant Accounting Policies HTML 135K
29: R12 U.K. Sale HTML 212K
30: R13 The CARES Act HTML 42K
31: R14 Revenue HTML 166K
32: R15 Earnings Per Share HTML 138K
33: R16 Acquisitions HTML 81K
34: R17 Property and Equipment HTML 68K
35: R18 Other Intangible Assets HTML 112K
36: R19 Leases HTML 240K
37: R20 Long-Term Debt HTML 134K
38: R21 Equity HTML 41K
39: R22 Equity-Based Compensation HTML 276K
40: R23 Income Taxes HTML 300K
41: R24 Derivatives HTML 42K
42: R25 Fair Value Measurements HTML 109K
43: R26 Commitments and Contingencies HTML 46K
44: R27 Noncontrolling Interests HTML 58K
45: R28 Employee Benefit Plans HTML 42K
46: R29 Accumulated Other Comprehensive Loss HTML 131K
47: R30 Quarterly Information (Unaudited) HTML 234K
48: R31 Financial Information for the Company and Its HTML 87K
Subsidiaries
49: R32 Subsequent Events HTML 41K
50: R33 Summary of Significant Accounting Policies HTML 159K
(Policies)
51: R34 Summary of Significant Accounting Policies HTML 113K
(Tables)
52: R35 U.K. Sale (Tables) HTML 216K
53: R36 Revenue (Tables) HTML 151K
54: R37 Earnings Per Share (Tables) HTML 136K
55: R38 Acquisitions (Tables) HTML 81K
56: R39 Property and Equipment (Tables) HTML 67K
57: R40 Other Intangible Assets (Tables) HTML 111K
58: R41 Leases (Tables) HTML 244K
59: R42 Long-Term Debt (Tables) HTML 112K
60: R43 Equity-Based Compensation (Tables) HTML 273K
61: R44 Income Taxes (Tables) HTML 299K
62: R45 Fair Value Measurements (Tables) HTML 106K
63: R46 Noncontrolling Interests (Tables) HTML 56K
64: R47 Accumulated Other Comprehensive Loss (Tables) HTML 131K
65: R48 Quarterly Information (Unaudited) (Tables) HTML 233K
66: R49 Financial Information for the Company and Its HTML 87K
Subsidiaries (Tables)
67: R50 Description of Business and Basis of Presentation HTML 44K
- Additional Information (Detail)
68: R51 Summary of Significant Accounting Policies - HTML 120K
Additional Information (Detail)
69: R52 Summary of Significant Accounting Policies - Other HTML 56K
Current Assets (Detail)
70: R53 Summary of Significant Accounting Policies - HTML 60K
Summary of Other Accrued Liabilities (Detail)
71: R54 U.K. Sale - Additional Information (Detail) HTML 74K
72: R55 U.K. Sale - Result of Operation (Detail) HTML 86K
73: R56 U.K. Sale - Major Classes of Assets and HTML 100K
Liabilities (Detail)
74: R57 U.K. Sale - Summary of Funded Status (Unfunded HTML 50K
Liability) (Detail)
75: R58 The CARES Act - Additional Information (Detail) HTML 79K
76: R59 Revenue - Additional Information (Detail) HTML 66K
77: R60 Revenue - Schedule of U.S. Revenue Attributed to HTML 58K
Each Category (Detail)
78: R61 Revenue - Schedule of Revenue and Percentage HTML 67K
Generated by Each Payor Type in U.S Facilities
(Detail)
79: R62 Revenue - Summary of the Activity in Unearned HTML 45K
Revenue in U.S. Facilities (Detail)
80: R63 Earnings Per Share - Computation of Basic and HTML 103K
Diluted Earnings Per Share (Detail)
81: R64 Earnings Per Share - Additional Information HTML 39K
(Detail)
82: R65 Acquisitions - Additional Information (Detail) HTML 52K
83: R66 Acquisitions - Summary of Changes in Goodwill HTML 46K
(Detail)
84: R67 Acquisitions - Transaction Related Expenses as HTML 46K
Incurred (Detail)
85: R68 Property and Equipment - Summary of Property and HTML 53K
Equipment (Detail)
86: R69 Property and Equipment - Additional information HTML 43K
(Detail)
87: R70 Other Intangible Assets - Other Identifiable HTML 63K
Intangible Assets and Related Accumulated
Amortization (Detail)
88: R71 Other Intangible Assets - Additional Information HTML 39K
(Detail)
89: R72 Leases - Additional Information (Detail) HTML 44K
90: R73 Leases - Schedule of Leases on Consolidated HTML 65K
Balance Sheet (Detail)
91: R74 Leases - Schedule of Weighted-average Remaining HTML 46K
Lease Terms and Discount Rates (Detail)
92: R75 Leases - Schedule of Lease Cost (Detail) HTML 56K
93: R76 Leases - Schedule of Undiscounted Cash Flows for HTML 86K
Finance and Operating Leases (Detail)
94: R77 Leases - Schedule of Supplemental Data (Detail) HTML 48K
95: R78 Long-Term Debt - Components of Long-Term Debt HTML 74K
(Detail)
96: R79 Long-Term Debt - Components of Long-Term Debt HTML 61K
(Parenthetical) (Detail)
97: R80 Long-Term Debt (Amended and Restated Senior Credit HTML 165K
Facility) - Additional Information (Detail)
98: R81 Long-Term Debt (6.125% Senior Notes due 2021) - HTML 47K
Additional Information (Detail)
99: R82 Long-Term Debt (5.125% Senior Notes due 2022) - HTML 47K
Additional Information (Detail)
100: R83 Long-Term Debt (Redemption of 6.125% Senior Notes HTML 52K
and 5.125% Senior Notes) - Additional Information
(Detail)
101: R84 Long-Term Debt (5.625% Senior Notes due 2023) - HTML 50K
Additional Information (Detail)
102: R85 Long-Term Debt (6.500% Senior Notes due 2024) - HTML 47K
Additional Information (Detail)
103: R86 Long-Term Debt (Redemption of 5.265% Senior Notes HTML 59K
and 6.500% Senior Notes) - Additional Information
(Detail)
104: R87 Long-Term Debt (5.500% Senior Notes due 2028) - HTML 47K
Additional Information (Detail)
105: R88 Long-Term Debt (5.000% Senior Notes due 2029) - HTML 53K
Additional Information (Detail)
106: R89 Long-Term Debt (9.0% and 9.5% Revenue Bonds) - HTML 64K
Additional Information (Detail)
107: R90 Long-Term Debt (Debt Issuance Costs) - Additional HTML 43K
Information (Detail)
108: R91 Long-Term Debt (Other) - Summary of Aggregate HTML 52K
Maturities of Long-Term Debt (Detail)
109: R92 Equity - Additional Information (Detail) HTML 45K
110: R93 Equity-Based Compensation - Additional Information HTML 74K
(Detail)
111: R94 Equity-Based Compensation - Stock Option Activity HTML 82K
(Detail)
112: R95 Equity-Based Compensation - Schedule of Stock HTML 47K
Options Valuation Assumptions (Detail)
113: R96 Equity-Based Compensation - Restricted Stock HTML 59K
Activity (Detail)
114: R97 Equity-Based Compensation - Restricted Stock Unit HTML 64K
Activity (Detail)
115: R98 Income Taxes - Components of Provision for Income HTML 65K
Taxes (Detail)
116: R99 Income Taxes - Effective Income Tax Rate (Detail) HTML 68K
117: R100 Income Taxes - Additional Information (Detail) HTML 108K
118: R101 Income Taxes - Summary of Domestic and Foreign HTML 46K
Components of Income from Continuing Operations
before Income Taxes (Detail)
119: R102 Income Taxes - Deferred Tax Assets and Liabilities HTML 83K
(Detail)
120: R103 Income Taxes - Unrecognized Income Tax Benefits HTML 43K
Net of Federal Benefit (Detail)
121: R104 Derivatives - Additional Information (Detail) HTML 48K
122: R105 Fair Value Measurements - Carrying Amounts and HTML 82K
Fair Values of Company's Amended and Restated
Senior Credit Facilities and Contingent
Consideration Liabilities (Detail)
123: R106 Fair Value Measurements - Additional Information HTML 56K
(Detail)
124: R107 Commitments and Contingencies - Additional HTML 38K
Information (Detail)
125: R108 Noncontrolling Interests - Additional Information HTML 45K
(Detail)
126: R109 Noncontrolling Interests - Summary of Redeemable HTML 47K
Noncontrolling Interests (Detail)
127: R110 Employee Benefit Plans - Additional Information HTML 41K
(Detail)
128: R111 Accumulated Other Comprehensive Loss - Components HTML 62K
of Accumulated Other Comprehensive Loss (Detail)
129: R112 Accumulated Other Comprehensive Loss - Components HTML 42K
of Accumulated Other Comprehensive Loss
(Parenthetical) (Detail)
130: R113 Quarterly Information (Unaudited) - Schedule of HTML 100K
Quarterly Financial Information (Detail)
131: R114 Quarterly Information (Unaudited) - Schedule of HTML 47K
Quarterly Financial Information (Parenthetical)
(Detail)
132: R115 Financial Information for the Company and Its HTML 56K
Subsidiaries - Additional Information (Detail)
133: R116 Financial Information for the Company and Its HTML 76K
Subsidiaries - Summarized Balance Sheet (Detail)
134: R117 Financial Information for the Company and Its HTML 70K
Subsidiaries - Summarized Statements of Income
(Loss) (Detail)
135: R118 Subsequent Events - Additional Information HTML 87K
(Detail)
137: XML IDEA XML File -- Filing Summary XML 262K
17: XML XBRL Instance -- achc-10k_20201231_htm XML 5.55M
136: EXCEL IDEA Workbook of Financial Reports XLSX 167K
13: EX-101.CAL XBRL Calculations -- achc-20201231_cal XML 396K
14: EX-101.DEF XBRL Definitions -- achc-20201231_def XML 1.01M
15: EX-101.LAB XBRL Labels -- achc-20201231_lab XML 2.04M
16: EX-101.PRE XBRL Presentations -- achc-20201231_pre XML 1.79M
12: EX-101.SCH XBRL Schema -- achc-20201231 XSD 322K
138: JSON XBRL Instance as JSON Data -- MetaLinks 611± 973K
139: ZIP XBRL Zipped Folder -- 0001564590-21-009466-xbrl Zip 473K
Exhibit 4.13
DESCRIPTION OF THE COMPANY’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES
EXCHANGE ACT OF 1934
Acadia Healthcare Company, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.01 par value per share.
In this exhibit, when we refer to “Acadia,” the “Company,” “we,” “us” or “our” or when we otherwise refer to ourselves, we mean Acadia Healthcare Company, Inc., excluding, unless otherwise expressly stated or the context requires, our subsidiaries; all references to “common stock” refer only to common stock issued by us and not to any common stock issued by any subsidiary.
DESCRIPTION OF COMMON STOCK
Our amended and restated certificate of incorporation, as amended, provides that our authorized capital stock consists of 180,000,000 shares of common stock, $0.01 par value, and 10,000,000 shares of preferred stock, $0.01 par value. As of February 26, 2021, there were 89,039,946 shares of our common stock and no shares of our preferred stock issued and outstanding.
This section summarizes the general terms of our common stock. The summaries in this section do not describe every aspect of our common stock. When evaluating our common stock, you should also refer to all of the provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and the Delaware General Corporation Law, as amended (“DGCL”). Our amended and restated certificate of incorporation and our amended and restated bylaws are filed as exhibits to our Annual Report on Form 10-K.
Terms of Common Stock
Voting Rights
Each share of common stock entitles the holder to one vote with respect to each matter presented to our stockholders on which the holders of common stock are entitled to vote. Our common stock votes as a single class on all matters relating to the election and removal of directors on our board of directors and as provided by law. Holders of our common stock do not have cumulative voting rights. Except in respect of matters relating to the election of directors, or as otherwise provided in our amended and restated certificate of incorporation or required by law, all matters to be voted on by our stockholders must be approved by a majority of the shares present in person or by proxy at the meeting at which a quorum is present and entitled to vote on the subject matter. The holders of a majority of the outstanding voting power of all shares of capital stock entitled to vote, present in person or represented by proxy, constitutes a quorum at all meetings of our stockholders. In the case of the election of directors in uncontested director elections, in order to be elected, a majority of the votes cast must be in favor of a nominee’s election. In contested elections, directors must be elected by a plurality of the votes cast.
Dividend Rights
The holders of our outstanding shares of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. Our ability to pay dividends on our common stock will be limited by restrictions on the ability of our subsidiaries to pay dividends or make distributions to us, including restrictions under the terms of the agreements governing our indebtedness.
Liquidation Rights
In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, holders of our common stock are entitled to share ratably in our assets that are legally available for distribution to stockholders
1
after payment of our debts and other liabilities. If we have any preferred stock outstanding at such time, holders of the preferred stock may be entitled to distribution and/or liquidation preferences. In either such case, we must pay the applicable distribution to the holders of preferred stock, if any, before we may pay distributions to the holders of our common stock.
Other Rights
Our stockholders have no preemptive, conversion or other rights to subscribe for additional shares. All outstanding shares of our common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that our board of directors may designate and issue in the future.
Listing
Our common stock is listed on The NASDAQ Global Select Market under the symbol “ACHC”.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc.
Registration Rights
Effective December 31, 2015, concurrently with the execution of the sale and purchase deed related to our acquisition of Priory Group No. 1 Limited, we entered into a third amended and restated registration rights agreement (the “Registration Rights Agreement”), with certain members of our current and former management (the “Management Investors”), Waud Capital Partners, L.L.C. (“WCP”), investment funds affiliated with Bain Capital Partners, LLC (collectively, “Bain Capital”) and investment funds affiliated with Advent International Corporation (“Advent”). The Registration Rights Agreement grants certain stockholders “demand” registration rights for registered offerings and “piggyback” registration rights with respect to our securities. Such rights expired for Bain Capital and Advent in connection with their prior sales of Acadia stock. All expenses incident to registrations are required to be borne by us.
Stockholders Agreement
Concurrently with the execution of the merger agreement related to our acquisition of CRC Health Group, Inc. (“CRC”), we entered into an amended and restated stockholders agreement (the “Stockholders Agreement”) with the Management Investors, WCP and Bain Capital. The Stockholders Agreement became effective on February 11, 2015 in connection with the closing of our acquisition of CRC.
The Stockholders Agreement granted WCP certain rights to designate a nominee for election to our board of directors which WCP exercised to designate Reeve B. Waud for election at the annual meeting of stockholders held in 2016 and certain consent rights over the transfer of shares by Management Investors that have expired.
The Stockholders Agreement provides that no Management Investor will take any of the following actions from the date the Company gives notice to the Management Investors that a preliminary or final prospectus has been circulated for a public offering and during the 60 days following the date of the final prospectus for such public offering: (i) offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any of the Company’s or its subsidiaries’ equity securities or any securities convertible into or exchangeable or exercisable for such securities; (ii) enter into any transaction which would have the same effect as described in clause (i); (iii) enter into any swap, hedge or other arrangement that transfers, in whole or part, any of the economic consequences or ownership of any of the securities described in clause (i); or (iv) publicly disclose the intention to enter into any transaction described in clauses (i), (ii) or (iii). The foregoing restrictions do not apply to transactions made in the subject public offering and those to which the underwriters managing such public offering agree in writing. As used
2
in this “– Stockholders Agreement” section, “public offering” refers to any offering by the Company of the Company’s or its subsidiaries’ capital stock or other equity securities to the public pursuant to an effective registration statement under the Securities Act or any comparable statement under any similar federal statute then in force.
Antitakeover Effects of Delaware Law and Acadia’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws
Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may delay, defer or discourage another party from acquiring control of us. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give our board of directors the power to discourage acquisitions that some stockholders may favor.
Undesignated Preferred Stock
The ability to authorize undesignated preferred stock will make it possible for our board of directors to issue preferred stock with super voting, special approval, dividend or other rights or preferences on a discriminatory basis that could impede the success of any attempt to acquire us. These and other provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in our control or our management.
Classified Board of Directors
In accordance with our amended and restated certificate of incorporation our board of directors is divided into three classes, with each class serving three-year staggered terms. In addition, under the DGCL, directors serving on a classified board of directors may only be removed from the board of directors with cause and by an affirmative vote of the majority of our common stock. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in our control or our management.
Requirements for Advance Notification of Stockholder Meetings
In accordance with our amended and restated certificate of incorporation, special meetings of the stockholders may be called only upon a resolution approved by a majority of our board of directors then in office.
Requirements for Nominations and Proposals at Stockholder Meetings
Our amended and restated bylaws prohibit the conduct of any business at a special meeting other than as brought by or at the direction of our board of directors. In accordance with our amended and restated bylaws, nominations of persons for election to our board of directors may be made at a special meeting of stockholders at which directors are to be elected pursuant to the notice of meeting (1) by or at the direction of our board of directors or (2) provided that our board of directors has determined that directors will be elected at such special meeting, by any holder of our stock who (i) is a stockholder of record both at the time the notice is delivered and on the record date for the determination of stockholders entitled to vote at such meeting, (ii) is entitled to vote at the meeting and upon such election, and (iii) complies with the notice procedures set forth in our amended and restated bylaws. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in our control or our management.
Stockholder Action by Written Consent
Pursuant to Section 228 of the DGCL, any action required to be taken at any annual or special meeting of our stockholders may be taken without a meeting, without prior notice and without a vote if a consent or consents in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and voted, unless the related certificate of incorporation provides
3
otherwise. Our amended and restated certificate of incorporation provides that any action required or permitted to be taken by our stockholders may be effected at a duly called annual or special meeting of our stockholders and may not be effected by consent in writing by such stockholders.
Business Combinations with Interested Stockholders
In accordance with our amended and restated certificate of incorporation we are not subject to Section 203 of the DGCL, an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination, such as a merger, with a person or group owning 15% or more of the corporation’s voting stock for a period of three years following the date the person became an interested stockholder, unless (with certain exceptions) the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Accordingly, we will not be subject to any anti-takeover effects of Section 203 of the DGCL. However, our amended and restated certificate of incorporation contains provisions that have the same effect as Section 203, except that they provide that WCP, any investment fund managed by WCP and any of their respective Affiliates and Associates (each as defined in our amended and restated certificate of incorporation) with whom any of the foregoing are acting as a group or in concert for the purpose of acquiring, holding, voting or disposing shares of our stock and any persons to whom WCP sells at least five percent (5%) of our outstanding voting stock will be deemed to have been approved by our board of directors, and thereby not subject to the restrictions set forth in our amended and restated certificate of incorporation that have the same effect as Section 203 of the DGCL.
Requirements for Amendments to Acadia’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws
The DGCL provides that in order to amend the certificate of incorporation, the board of directors must adopt a resolution that then must be approved by the affirmative vote of a majority of the voting power of the outstanding stock entitled to vote thereon, unless a greater vote is specified in the certificate of incorporation, and subject to any additional vote required by any series of preferred stock. In accordance with our amended and restated certificate of incorporation, the articles relating to the following topics may only be amended, altered, changed or repealed by the affirmative vote of the holders of at least a majority of the voting power of all of our outstanding shares of capital stock entitled to vote generally in the election of directors, other than shares of any “Interested Stockholder” (as defined in our amended and restated certificate of incorporation): Board of Directors (Article Six); Limitation of Director Liability (Article Seven); Limitations on Written Consent/Special Meetings (Article Eight); Business Combinations (Article Ten); Poison Pill (Article Eleven); Amendments (Article Twelve); Forum Selection (Article Thirteen); and Severability (Article Fourteen). Our amended and restated certificate of incorporation also provides that Article Nine, which deals with corporate opportunity, may only be amended, altered or repealed by a vote of 80% of the voting power of all of our shares of common stock then outstanding, voting together as a single class. See “—Corporate Opportunity.”
Our amended and restated certificate of incorporation provides that our amended and restated bylaws may be adopted, amended, altered or repealed by the affirmative vote of a majority of our board of directors. In addition, our bylaws may be adopted, amended, altered or repealed by the affirmative vote of the stockholders having at least a majority of the voting power of all of the then outstanding shares of our capital stock, voting together as a single class.
Corporate Opportunity
Our amended and restated certificate of incorporation provides that the doctrine of “corporate opportunity” does not apply against WCP, its affiliates, any investment fund managed by WCP or any of their respective portfolio companies or their respective partners, members, directors, employees, stockholders, agents or successors, in a manner that would prohibit them from investing in competing businesses or doing business with Acadia’s clients or customers. If the ownership of our common stock continues to be highly concentrated, it may prevent you and other stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause our stock price to decline.
4
Limitation on Liability and Indemnification of Officers and Directors
In accordance with our amended and restated bylaws, we must indemnify our directors and officers to the fullest extent authorized by the DGCL and must also pay expenses incurred in defending any such proceeding in advance of its final disposition upon delivery of an undertaking, by or on behalf of an indemnified person, to repay all amounts so advanced if it should be determined ultimately that such person is not entitled to be indemnified.
We entered into indemnification agreements with each of our current directors and executive officers. These agreements require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.
The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, provision of our amended and restated certificate of incorporation, our amended and restated bylaws, agreement, vote of stockholders or disinterested directors or otherwise.
5
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/26/21 | 4, 8-K | ||
| For Period end: | 12/31/20 | |||
| 12/31/15 | 10-K, 8-K | |||
| 2/11/15 | 3, 8-K, SC 13G/A | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/24 Acadia Healthcare Co., Inc. 10-K 12/31/23 128:15M Donnelley … Solutions/FA 2/28/23 Acadia Healthcare Co., Inc. 10-K 12/31/22 133:18M ActiveDisclosure/FA 3/01/22 Acadia Healthcare Co., Inc. 10-K 12/31/21 135:19M ActiveDisclosure/FA 8/03/21 Acadia Healthcare Co., Inc. S-8 8/03/21 3:78K Donnelley … Solutions/FA |